CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 82 enrolled
Drug / intervention
Lenalidomide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02272803
NCT02272803Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan

Bristol-Myers Squibb·interventional·Posted Oct 23, 2014·Updated Jun 22, 2022

In Brief

A Phase 2 clinical trial evaluating Lenalidomide, Dexamethasone, and 1 other intervention for Multiple Myeloma. Completed, enrolled 82 participants across 28 sites.

Detailed Summary

The purpose of this study is to determine the efficacy of Lenalidomide/Dexamethasone + Elotuzumab in the subjects with newly diagnosed, previously untreated Multiple Myeloma (MM) in Japan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesJapan
CollaboratorsAbbVie

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 23, 2014
Enrollment StartFeb 20, 2015
Primary CompletionFeb 9, 2017
Study CompletionJul 21, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 11.7 years ago

Interventions

Lenalidomidedrug

Dexamethasonedrug

Elotuzumab (BMS-901608)biological